1. positive igm/igg against sars-cov-2 prior to randomization. 2. severeor critical illness 3. uncontrolled hypertension, cardiovascular/cerebrovascular diseases,lung diseases 4. type 1 diabetes, or newly diagnosed or poorly controlled type 2 diabetes 5. liver and kidney dysfunction, immune or inflammatory diseases, infections, surgery, tumors, and other major diseases 6. history of sars-cov-2 vaccination or participation in clinical trial with neutralizing antibody against sars-cov-2. 7. use of therapeutic biologics within 3 months prior to screening, or within the elimination period (5 half-lives) of such drugs as the day of dosing 8. has participated in any other interventional clinical study involving anstudy drug within 3 months prior to screening, or within the elimination period (5 half-lives) of the study drug as the day of dosing 9. platelets and hemoglobin test results during screening period are abnormal and have clinical significanc. 10. anaphylaxis, urine drug screening, alcohol dependence, lactation during pregnancy, blood loss, and others

1. positive igm/igg against sars-cov-2 prior to randomization. 2. severeor critical illness 3. uncontrolled hypertension, cardiovascular/cerebrovascular diseases,lung diseases 4. type 1 diabetes, or newly diagnosed or poorly controlled type 2 diabetes 5. liver and kidney dysfunction, immune or inflammatory diseases, infections, surgery, tumors, and other major diseases 6. history of sars-cov-2 vaccination or participation in clinical trial with neutralizing antibody against sars-cov-2. 7. use of therapeutic biologics within 3 months prior to screening, or within the elimination period (5 half-lives) of such drugs as the day of dosing 8. has participated in any other interventional clinical study involving anstudy drug within 3 months prior to screening, or within the elimination period (5 half-lives) of the study drug as the day of dosing 9. platelets and hemoglobin test results during screening period are abnormal and have clinical significanc. 10. anaphylaxis, urine drug screening, alcohol dependence, lactation during pregnancy, blood loss, and others

positive igm/igg against sars-cov-2 prior to randomization. severeor critical illness uncontrolled hypertension, cardiovascular/cerebrovascular diseases,lung diseases type 1 diabetes, or newly diagnosed or poorly controlled type 2 diabetes liver and kidney dysfunction, immune or inflammatory diseases, infections, surgery, tumors, and other major diseases history of sars-cov-2 vaccination or participation in clinical trial with neutralizing antibody against sars-cov-2. use of therapeutic biologics within 3 months prior to screening, or within the elimination period (5 half-lives) of such drugs as the day of dosing has participated in any other interventional clinical study involving anstudy drug within 3 months prior to screening, or within the elimination period (5 half-lives) of the study drug as the day of dosing platelets and hemoglobin test results during screening period are abnormal and have clinical significanc. anaphylaxis, urine drug screening, alcohol dependence, lactation during pregnancy, blood loss, and others

positive igm/igg against sars-cov-2 prior to randomization. severeor critical illness uncontrolled hypertension, cardiovascular/cerebrovascular diseases,lung diseases type 1 diabetes, or newly diagnosed or poorly controlled type 2 diabetes liver and kidney dysfunction, immune or inflammatory diseases, infections, surgery, tumors, and other major diseases history of sars-cov-2 vaccination or participation in clinical trial with neutralizing antibody against sars-cov-2. use of therapeutic biologics within 3 months prior to screening, or within the elimination period (5 half-lives) of such drugs as the day of dosing has participated in any other interventional clinical study involving anstudy drug within 3 months prior to screening, or within the elimination period (5 half-lives) of the study drug as the day of dosing platelets and hemoglobin test results during screening period are abnormal and have clinical significanc. anaphylaxis, urine drug screening, alcohol dependence, lactation during pregnancy, blood loss, and others

1. positive igm/igg against sars-cov-2 prior to randomization. 2. severeor critical illness 3. uncontrolled hypertension, cardiovascular/cerebrovascular diseases,lung diseases 4. type 1 diabetes, or newly diagnosed or poorly controlled type 2 diabetes 5. liver and kidney dysfunction, immune or inflammatory diseases, infections, surgery, tumors, and other major diseases 6. history of sars-cov-2 vaccination or participation in clinical trial with neutralizing antibody against sars-cov-2. 7. use of therapeutic biologics within 3 months prior to screening, or within the elimination period (5 half-lives) of such drugs as the day of dosing 8. has participated in any other interventional clinical study involving anstudy drug within 3 months prior to screening, or within the elimination period (5 half-lives) of the study drug as the day of dosing 9. platelets and hemoglobin test results during screening period are abnormal and have clinical significanc. 10. anaphylaxis, urine drug screening, alcohol dependence, lactation during pregnancy, blood loss, and others

1. positive igm/igg against sars-cov-2 prior to randomization. 2. severeor critical illness 3. uncontrolled hypertension, cardiovascular/cerebrovascular diseases,lung diseases 4. type 1 diabetes, or newly diagnosed or poorly controlled type 2 diabetes 5. liver and kidney dysfunction, immune or inflammatory diseases, infections, surgery, tumors, and other major diseases 6. history of sars-cov-2 vaccination or participation in clinical trial with neutralizing antibody against sars-cov-2. 7. use of therapeutic biologics within 3 months prior to screening, or within the elimination period (5 half-lives) of such drugs as the day of dosing 8. has participated in any other interventional clinical study involving anstudy drug within 3 months prior to screening, or within the elimination period (5 half-lives) of the study drug as the day of dosing 9. platelets and hemoglobin test results during screening period are abnormal and have clinical significanc. 10. anaphylaxis, urine drug screening, alcohol dependence, lactation during pregnancy, blood loss, and others